Anti-tau antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-12486319-B2
Application number	US-202218065472-A
Country	US
Kind code	B2
Filing date	Dec 13, 2022
Priority date	Jun 5, 2015
Publication date	Dec 2, 2025
Grant date	Dec 2, 2025

Abstract

The invention provides anti-Tau antibodies and methods of using the same.

First claim

What is claimed is:

1 . An isolated antibody that binds human Tau, wherein the antibody comprises:
a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 192; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 193; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 194; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 195; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 196; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 197.

2 . The isolated antibody of to claim 1 , wherein the antibody comprises: a) a heavy chain variable region (VH) comprising a sequence that is at least 95% identical to SEQ ID NO: 190; b) a light chain variable region (VL) comprising a sequence that is at least 95% identical to SEQ ID NO: 191; or c) a VH as in (a) and a VL as in (b).

3 . The isolated antibody of claim 1 , wherein the antibody comprises: a) a heavy chain variable region (VH) comprising the sequence of SEQ ID NO: 190; b) a light chain variable region (VL) comprising the sequence of SEQ ID NO: 191; or c) a VH as in (a) and a VL as in (b).

4 . The isolated antibody of claim 1 , wherein the antibody is an IgG1 or an IgG4 antibody.

5 . The isolated antibody of claim 4 , wherein the antibody is an IgG4 antibody.

6 . The isolated antibody of claim 5 , wherein the antibody comprises M252Y, S254T, and T256E mutations.

7 . The isolated antibody of claim 5 , wherein the antibody comprises an S228P mutation.

8 . The isolated antibody of claim 1 , wherein the antibody binds each of monomeric Tau, phosphorylated Tau, non-phosphorylated Tau, and oligomeric Tau with a KD of less than 100 nM.

9 . An isolated nucleic acid that encodes the antibody of claim 1 .

10 . An isolated host cell comprising the nucleic acid of claim 9 .

11 . A method of producing an antibody comprising culturing the host cell of claim 10 under conditions suitable for producing the antibody.

12 . An immunoconjugate comprising the antibody of claim 1 and a second therapeutic agent.

13 . A labeled antibody comprising the antibody of claim 1 and a detectable label.

14 . A pharmaceutical composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable carrier.

15 . The isolated antibody of claim 1 , which is a monoclonal antibody.

16 . The isolated antibody of claim 1 , which is a humanized or chimeric antibody.

17 . The isolated antibody of claim 1 , which is an antibody fragment that binds human Tau.

Assignees

• Genentech Inc
• Ac Immune Sa

Inventors

• Adolfsson Oskar
• Ayalon Gai
• Hotzel Isidro
• Di Cara Danielle Marie

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• A61K2039/505

  comprising antibodies · CPC title